Prosthetic joint infection treatment market projected to hit $154.2 million by 2033

The global prosthetic joint infection treatment market is forecast to grow from $110.3 million in 2026 to $154.2 million by 2033, driven by rising joint replacement surgeries and better infection detection. North America leads the market now, while hospitals remain the top end-user segment.

Why it matters: - Prosthetic joint infections are a serious complication after orthopedic implant surgery and often require long, specialized treatment. - Demand for infection treatment rises as more hip and knee replacements are performed worldwide. - The market outlook signals continued spending on antibiotics, surgery and diagnostics tied to post-implant care.

What happened: - Persistence Market Research projects the global prosthetic joint infection treatment market will grow from US$ 110.3 million in 2026 to US$ 154.2 million by 2033. - The forecast implies a 4.9% compound annual growth rate over the period. - The report says North America leads the market because of high joint replacement volume and strong healthcare infrastructure.

The details: - Antibiotic therapy remains a leading treatment option because of its role in infection control. - Hospitals account for the largest end-user share because of advanced surgical and post-operative care capabilities. - Market treatment options include antibiotic therapy, surgical intervention, debridement procedures and revision surgeries. - Antibiotic therapy is widely used with surgery to help manage infection and reduce recurrence. - End users also include orthopedic clinics and specialty care centers. - North America benefits from greater adoption of advanced diagnostic and treatment technologies. - Europe remains an important market because of an aging population and higher demand for joint replacement surgery. - Asia Pacific is emerging as a growth region as healthcare infrastructure expands and access to orthopedic treatment improves. - Rising osteoarthritis and age-related joint disorders are increasing the need for prosthetic implants. - High treatment costs, long treatment durations, multiple surgeries and antibiotic resistance remain barriers. - Investment in infection prevention strategies and advanced antimicrobial therapies is creating opportunity. - Expanding healthcare facilities in emerging economies should also support growth. - Companies named in the report include Zimmer Biomet, Johnson & Johnson, Stryker Corporation, Smith+Nephew, B. Braun SE, Pfizer Inc., Merck & Co., Inc., Abbott, Medtronic plc and Heraeus Holding GmbH. - The report offers a free sample at More information and customization at Request report customization. - The full report is available at Buy the full report.

Between the lines: - The forecast points to a niche but durable segment tied to the broader growth in orthopedic implant procedures. - The market structure favors hospitals and antibiotic-based care, which suggests treatment complexity still keeps care concentrated in advanced facilities. - Regional leadership remains with North America, but Europe and Asia Pacific could narrow the gap as demographics and infrastructure change.

What's next: - Market growth will likely track future volumes of hip and knee replacements. - Advances in diagnostics and antimicrobial therapies could improve early detection and treatment outcomes. - Healthcare expansion in emerging markets may widen access to prosthetic joint infection care. - Ongoing concerns about cost and antibiotic resistance may shape product development and treatment strategy.